Targeting IGF2BP3 in Cancer.
Xin LiuJiayu ChenWenliang ChenYangtao XuYang ShenXiming XuPublished in: International journal of molecular sciences (2023)
RNA-binding proteins (RBPs) can regulate multiple pathways by binding to RNAs, playing a variety of functions, such as localization, stability, and immunity. In recent years, with the development of technology, researchers have discovered that RBPs play a key role in the N6-methyladenosine (m6A) modification process. M6A methylation is the most abundant form of RNA modification in eukaryotes, which is defined as methylation on the sixth N atom of adenine in RNA. Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) is one of the components of m6A binding proteins, which plays an important role in decoding m6A marks and performing various biological functions. IGF2BP3 is abnormally expressed in many human cancers, often associated with poor prognosis. Here, we summarize the physiological role of IGF2BP3 in organisms and describe its role and mechanism in tumors. These data suggest that IGF2BP3 may be a valuable therapeutic target and prognostic marker in the future.
Keyphrases
- binding protein
- poor prognosis
- growth hormone
- pi k akt
- long non coding rna
- dna methylation
- genome wide
- endothelial cells
- papillary thyroid
- gene expression
- molecular dynamics
- signaling pathway
- electronic health record
- cancer therapy
- current status
- squamous cell
- childhood cancer
- artificial intelligence
- gram negative
- big data
- multidrug resistant